Psoriasis

AAD and NPF Issue Two New Psoriasis Guidelines

The American Academy of Dermatology and National Psoriasis Foundation have released 2 joint guidelines for the management and treatment of psoriasis.1,2

 

Based on current available evidence, the new guidelines are the first 2 of a series of 6 psoriasis guidelines to be released this year.3

YOU MIGHT LIKE
Biologics May Be Cardioprotective in Psoriasis
Q&A: Screening for PsA in Psoriasis is Key

One set of guidelines addresses common extracutaneous manifestations associated with psoriasis, including psoriatic arthritis, cardiovascular disease, metabolic syndrome, mental health conditions, and inflammatory bowel disease, and how the presence of these comorbidities can affect management of a patient’s psoriasis.1

 

The second set of guidelines discusses the treatment of psoriasis using biologics, including:

 

  • Tumor necrosis factor alpha inhibitors, such as etanercept, infliximab, adalimumab, and certolizumab.
  • Interleukin (IL)-12/IL-23 inhibitors, such as ustekinumab.
  • IL-17 inhibitors, such as secukinumab, ixekizumab, and brodalumab.
  • IL-23 inhibitors, such as guselkumab, tildrakizumab, and risankizumab.2

 

“We believe this guideline will be a vital resource in the treatment of psoriasis,” said board-certified dermatologist Craig A. Elmets, MD, FAAD, co-chair of the work group that constructed the guidelines, in a press release.3

 

“Doctors should be aware of the conditions associated with this disease, educate patients accordingly, and work with those patients and other physicians to ensure that each patient receives the appropriate screening and treatment,” Dr Elmets said.3

 

—Christina Vogt

 

References:

 

1. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities [Published online February 13, 2019]. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.11.058.

 

2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics [Published online February 13, 2019]. J Am Acad Dermatol.

 

3. Two new psoriasis guidelines address comorbidities, biologic treatment [press release]. Rosemont, IL. American Academy of Dermatology. February 13, 2019. https://www.aad.org/media/news-releases/two-new-psoriasis-guidelines-comorbidities-and-biologics. Accessed on February 13, 2019.